vs
Side-by-side financial comparison of Information Services Group Inc. (III) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $61.2M, roughly 1.4× Information Services Group Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 5.9%). Information Services Group Inc. produced more free cash flow last quarter ($4.3M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.4%).
EBSCO Information Services, headquartered in Ipswich, Massachusetts, is a division of EBSCO Industries Inc., a private company headquartered in Birmingham, Alabama. EBSCO provides products and services to libraries of many types around the world. Its products include EBSCONET, a complete e-resource management system, and EBSCOhost, which supplies a fee-based online research service with 375 full-text databases, a collection of 600,000-plus ebooks, subject indexes, point-of-care medical refere...
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
III vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.2M | $86.8M |
| Net Profit | $2.6M | — |
| Gross Margin | 44.8% | 67.4% |
| Operating Margin | 8.4% | -84.7% |
| Net Margin | 4.3% | — |
| Revenue YoY | 5.9% | 17.7% |
| Net Profit YoY | -14.1% | — |
| EPS (diluted) | $0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.2M | $86.8M | ||
| Q3 25 | $62.4M | $67.5M | ||
| Q2 25 | $61.6M | $60.0M | ||
| Q1 25 | $59.6M | $49.3M | ||
| Q4 24 | $57.8M | $73.7M | ||
| Q3 24 | $61.3M | $58.6M | ||
| Q2 24 | $64.3M | $31.1M | ||
| Q1 24 | $64.3M | $715.0K |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $3.1M | $-91.3M | ||
| Q2 25 | $2.2M | $-111.7M | ||
| Q1 25 | $1.5M | $-116.2M | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $1.1M | $-83.5M | ||
| Q2 24 | $2.0M | $-97.1M | ||
| Q1 24 | $-3.4M | $-113.0M |
| Q4 25 | 44.8% | 67.4% | ||
| Q3 25 | 42.2% | 43.0% | ||
| Q2 25 | 42.2% | 5.5% | ||
| Q1 25 | 43.1% | -0.8% | ||
| Q4 24 | 41.5% | 68.7% | ||
| Q3 24 | 40.4% | 46.2% | ||
| Q2 24 | 39.5% | -0.8% | ||
| Q1 24 | 36.1% | — |
| Q4 25 | 8.4% | -84.7% | ||
| Q3 25 | 7.4% | -140.7% | ||
| Q2 25 | 7.6% | -189.8% | ||
| Q1 25 | 5.7% | -245.8% | ||
| Q4 24 | 0.3% | -117.5% | ||
| Q3 24 | 7.0% | -152.1% | ||
| Q2 24 | 5.7% | -327.6% | ||
| Q1 24 | -3.7% | -16464.6% |
| Q4 25 | 4.3% | — | ||
| Q3 25 | 4.9% | -135.3% | ||
| Q2 25 | 3.5% | -186.2% | ||
| Q1 25 | 2.5% | -235.5% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 1.9% | -142.7% | ||
| Q2 24 | 3.2% | -312.2% | ||
| Q1 24 | -5.3% | -15800.8% |
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.04 | $-0.33 | ||
| Q1 25 | $0.03 | $-0.36 | ||
| Q4 24 | $0.07 | $-0.24 | ||
| Q3 24 | $0.02 | $-0.28 | ||
| Q2 24 | $0.04 | $-0.34 | ||
| Q1 24 | $-0.07 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.7M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $94.7M | $698.6M |
| Total Assets | $211.0M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.7M | $297.0M | ||
| Q3 25 | $28.7M | $300.8M | ||
| Q2 25 | $25.2M | $301.2M | ||
| Q1 25 | $20.1M | $359.7M | ||
| Q4 24 | $23.1M | $323.8M | ||
| Q3 24 | $9.7M | $397.5M | ||
| Q2 24 | $11.8M | $412.5M | ||
| Q1 24 | $14.0M | $356.2M |
| Q4 25 | $94.7M | $698.6M | ||
| Q3 25 | $94.7M | $702.3M | ||
| Q2 25 | $94.1M | $698.5M | ||
| Q1 25 | $95.0M | $767.9M | ||
| Q4 24 | $96.3M | $710.4M | ||
| Q3 24 | $96.6M | $773.5M | ||
| Q2 24 | $95.5M | $768.5M | ||
| Q1 24 | $95.6M | $680.0M |
| Q4 25 | $211.0M | $913.2M | ||
| Q3 25 | $213.3M | $904.9M | ||
| Q2 25 | $200.7M | $907.4M | ||
| Q1 25 | $202.4M | $966.7M | ||
| Q4 24 | $204.5M | $910.4M | ||
| Q3 24 | $227.1M | $991.1M | ||
| Q2 24 | $235.3M | $964.3M | ||
| Q1 24 | $234.2M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.1M | $-52.6M |
| Free Cash FlowOCF − Capex | $4.3M | $-61.9M |
| FCF MarginFCF / Revenue | 7.0% | -71.3% |
| Capex IntensityCapex / Revenue | 1.2% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.94× | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.0M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $-52.6M | ||
| Q3 25 | $11.1M | $-78.7M | ||
| Q2 25 | $11.9M | $-67.4M | ||
| Q1 25 | $978.0K | $-103.7M | ||
| Q4 24 | $6.6M | $-73.3M | ||
| Q3 24 | $8.8M | $-59.0M | ||
| Q2 24 | $2.2M | $-98.4M | ||
| Q1 24 | $2.3M | $-122.3M |
| Q4 25 | $4.3M | $-61.9M | ||
| Q3 25 | $9.5M | $-89.5M | ||
| Q2 25 | $11.1M | $-74.9M | ||
| Q1 25 | $141.0K | $-109.9M | ||
| Q4 24 | $6.0M | $-77.5M | ||
| Q3 24 | $8.4M | $-61.3M | ||
| Q2 24 | $1.3M | $-98.9M | ||
| Q1 24 | $1.3M | $-126.5M |
| Q4 25 | 7.0% | -71.3% | ||
| Q3 25 | 15.2% | -132.7% | ||
| Q2 25 | 18.0% | -124.9% | ||
| Q1 25 | 0.2% | -222.8% | ||
| Q4 24 | 10.4% | -105.1% | ||
| Q3 24 | 13.7% | -104.6% | ||
| Q2 24 | 2.0% | -317.9% | ||
| Q1 24 | 2.0% | -17685.3% |
| Q4 25 | 1.2% | 10.7% | ||
| Q3 25 | 2.5% | 16.1% | ||
| Q2 25 | 1.4% | 12.4% | ||
| Q1 25 | 1.4% | 12.6% | ||
| Q4 24 | 0.9% | 5.7% | ||
| Q3 24 | 0.6% | 3.9% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 1.6% | 583.4% |
| Q4 25 | 1.94× | — | ||
| Q3 25 | 3.62× | — | ||
| Q2 25 | 5.46× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 2.15× | — | ||
| Q3 24 | 7.66× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
III
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
